Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 1, 1999, Pages 110-122

  Tolliver, Bryan K ^a   Newman, Amy H ^b   Katz, Jonathan L ^b   Ho, Lauren B ^a   Fox, Lisa M ^a   Hsu Jr , Kang ^a   Berger, S Paul ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CHLOROBENZTROPINE; BENZATROPINE; COCAINE; DOPAMINE TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONVULSION; DISCRIMINATIVE STIMULUS; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG POTENTIATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY;

ANIMALS; BEHAVIOR, ANIMAL; BENZTROPINE; CARRIER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COCAINE; DISCRIMINATION LEARNING; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; INJECTIONS, INTRAPERITONEAL; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICRODIALYSIS; MICROINJECTIONS; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032919493     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Acri JB, Seidleck BK and Witkin JM (1996) Effects of benztropine on behavioral and toxic effects of cocaine: Comparison with atropine and the selective dopamine uptake inhibitor 1-[2-(diphenylmethoxy)ethyll-4-(3-phenyl-propyl)-piperazine. J Pharmacol Exp Ther 277:198-206.
2. 3H]BTCP in rat caudate membranes. J Pharmacol Exp Ther 268:1462-1475.
3. Baumann MH, Char GU, De Costa BR, Rice KC and Rothman RB (1994) GBR 12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J Pharmacol Exp Ther 271:1216-1222.
4. Berger P, Elsworth JD, Reith MEA, Tanen D and Roth RH (1990) Complex interaction of cocaine with the dopamine uptake carrier. Eur J Pharmacol 176:251-252.
5. Bergman J, Madras BK, Johnson SE and Spealman RD (1989) Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 251:150-155.
6. Boja JW, Markham L, Patel A, Uhl G and Kuhar MJ (1992) Expression of a single dopamine transporter cDNA can confer two cocaine binding sites. NeuroReport 3:247-248.
7. Bradberry CW and Roth RH (1989) Cocaine increases extracellular dopamine in rat nucleus accumbens and ventral tegmental area as shown by in vivo microdialysis. Neurosci Lett 103:97-102.
8. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, Goodman JM, Kantor HL, Gastfriend DR, Riorden JP, Mathew RT, Rosen BR and Hyman SE (1997) Acute effects of cocaine on human brain activity and emotion. Neuron 19:591-611.
9. Carlton P (1961) Augmentation of the behavioral effects of amphetamine by scopolamine. Psychopharmacology 2:377-380.
10. Carroll FI, Lewin AH, Boja JW and Kuhar MJ (1992) Cocaine receptor: Biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J Med Chem 35:969-981.
11. Church WH, Justice JB and Byrd LD (1987) Extracellular dapamine in rat striatum following uptake inhibition by cocaine, nomifensine, and benztropine. Eur J Pharmacol 139:345-348.
12. Delfs JM, Schreiber L and Kelley AE (1990) Microinjection of cocaine into the nucleus accumbens elicits locomotor activation in the rat. J Neurosci 10:303-310.
13. 3H]mazindol binding to the dopamine transporter by a competitive mechanism: Preliminary evidence for different binding domains. Neurochem Res 19:201-208.
14. Di Chiara G and Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentration in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
15. Finney DJ (1964) Statistical Methods in Biological Assay,2nd ed., Hafner, New York.
16. Gawin F, Riordan C and Kleber H (1985) Methylphenidate treatment of cocaine abusers without attention deficit disorder: A negative report. Am J Drug Alcohol Abuse 11:193-197.
17. Gifford AN, Bergmann JS and Johnson KM (1993) GBR 12909 fails to antagonize cocaine-induced elevation of dopamine in striatal slices. Drug Alcohol Depend 32:65-71.
18. Giros B, Jaber M, Jones SR, Wightman RM and Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature (London) 379:606-612.
19. Glowa JR, Fantegrossi WE, Lewis DB, Matecka D, Rice KC and Rothman RB (1996) Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxy-3-phenylpropyl)piperazinyl decanoate, a long-acting ester derivative of GBR 12909. J Med Chem 39:4689-4691.
20. Heikkila RE and Manzino L (1984) Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: Specific inhibitors of dopamine uptake. Eur J Pharmacol 103: 241-248.
21. Hurd YL and Ungerstedt U (1989) Cocaine: An in vivo microdialysis evaluation of its acute action on dopamine transmission in rat striatum. Synapse 3:48-54.
22. Izenwasser S, Terry P, Heller B, Witkin JM and Katz JL (1994) Differential relationships among dopamine transporter affinities and stimulant potencies of various uptake inhibitors. Eur J Pharmacol 263:277-283.
23. Jaffe JH, Witkin JM, Goldberg SR and Katz JL (1989) Potential toxic interactions of cocaine and mazindol. Lancet 334:111.
24. Johanson CE and Fischman MW (1989) The pharmacology of cocaine related to its abuse. Pharmacol Rev 41:3-52.
25. Johnson DN and Vocci FJ (1993) Medications development at the National Institute on Drug Abuse: Focus on cocaine. NIDA Research Monograph 135:57-70.
26. Jones GH, Hooks MS, Juncos JL and Justice JB (1994) Effects of cocaine microinjections into the nucleus accumbens and medial prefrontal cortex on schedule-induced behavior: Comparison with systemic cocaine administration. Psychopharmacology 116:375-382.
27. Katz JL, Izenwasser S, Kline RH, Allen AC and Newman AH (1999) Novel 3α-diphenylmethoxytropane analogs: Selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. J Pharmacol Exp Ther 288:302-315.
28. Katz JL, Newman AH and Izenwasser S (1997) Relations between heterogeneity of dopamine transporter binding and function and the behavioral pharmacology of cocaine. Pharmacol Biochem Behav 57:505-512.
29. Kelly PH and Iversen SD (1976) Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: Abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 40:45-56.
30. Kennedy LT and Hanbauer I (1983) Sodium-sensitive cocaine binding to rat striatal membrane: Possible relationship to dopamine uptake sites. J Neurochem 41:172-178.
31. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM and Uhl GR (1992) Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA 89:7782-7785.
32. Kline RH, Izenwasser S, Katz JL, Joseph DB, Bowen WD and Newman AH (1997) 3′-chloro-3α-(diphenylmethoxy)tropane but not 4′-chloro-3α-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile. J Med Chem 40:851-857.
33. 3H]Cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 251:131-141.
34. Mogaddam B and Bunney BS (1989) Differential effect of cocaine on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens: Comparison to amphetamine. Synapse 4:156-161.
35. Newman AH, Allen AC, Izenwasser S and Katz JL (1994) Novel 3α-(diphenylmethoxy)tropane analogs: Potent dopamine uptake inhibitors without cocaine-like behavioral profiles. J Med Chem 37:2258-2261.
36. Newman AH, Kline RH, Allen AC, Izenwasser S, George C and Katz JL (1995) Novel 4′-substituted and 4′4″-disubstituted 3α-(diphenylmethoxy)tropane analogs as potent and selective dopamine uptake inhibitors. J Med Chem 38:3933-3940.
37. Nomikos GG, Damsma G, Wenkstern D and Fibiger HC (1990) In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 6:106-112.
38. Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates, Academic Press, San Diego.
39. Preston KL, Sullivan JT, Berger P and Bigelow GE (1993) Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J Pharmacol Exp Ther 267:296-307.
40. 3 receptor antagonists attenuate cocaine-induced locomotion in mice. Eur J Pharmacol 186:327-330
41. Reith MEA, de Costa BR, Rice KC and Jacobson AE (1992) Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur J Pharmacol 227:417-425.
42. Reith MEA, Meisler BE, Sershen H and Lajtha A (1986) Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brain and to induce stereotyped behavior. Biochem Pharmacol 35:1123-1129.
43. Ritz MC, Lamb RJ, Goldberg SR and Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219-1223.
44. Roberts DCS, Corcoran ME and Fibiger HC (1977) On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol Biochem Behav 6:615-620.
45. Roberts DCS, Zis AP and Fibiger HC (1975 ) Ascending catecholaminergic pathways and amphetamine-induced locomotor activity: Importance of dopamine and apparent noninvolvement of norepinephrine. Brain Res 93:441-451.
46. Rothman RB (1990) High affinity dopamine reuptake inhibitors as potential cocaine antagonists: A strategy for drug development. Life Sci 46:17-21.
47. Rothman RB and Glowa JR (1995) A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development: Focus on GBR 12909. Mol Neurobiol 11:1-19.
48. Rothman RB, Grieg N, Kim A, de Costa BK, Rice KC, Carroll FI and Pert A (1992) Cocaine and GBR 12909 produce equivalent motoric responses at different occupancy of the dopamine transporter. Pharmacol Biochem Behav 43:1135-1142.
49. Rothman RB, Mele A, Reid AA, Akunne HC, Grieg N, Thurkauf A, De Costa BR, Rice KC and Pert A (1991) GBR 12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol Biochem Behav 40:387-397.
50. Scheel-Kruger J (1972) Behavioral and biochemical comparison of amphetamine derivatives, cocaine, benztropine and tricyclic anti-depressant drugs. Eur J Pharmacol 18:63-73.
51. Sellers EM, Busto M and Kaplan HL (1989) Pharmacokinetic and pharmacodynamic drug interactions: Implications for abuse liability testing. NIDA Research Monograph 92:287-306.
52. Simoni D, Stoelwinder J, Kozikowski AP, Johnson KM, Bergmann JS and Ball RG (1993) Methoxylation of cocaine reduces binding affinity and produces compounds of differential binding and dopamine uptake inhibitory activity: Discovery of a weak cocaine "antagonist." J Med Chem 36:3975-3977.
53. Snedecor GW and Cochran CR (1967) Statistical Methods, 6th ed., Iowa State University Press, Ames, Iowa.
54. Snoddy AM and Tessel RE (1985) Prazosin: Effect on psychomotor stimulant cues and locomotor activity in mice. Eur J Pharmacol 116:221-228.
55. Spealman RD, Madras BK and Bergman J (1989) Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J Pharmacol Exp Ther 251:142-149.
56. Stathis M, Scheffel U, Lever SZ, Boja JW, Carroll FI and Kuhar MJ (1995) Rate of binding of various inhibitors at the dopamine transporter in vivo. Psychopharmacology 119:376-384.
57. Steketee JD and Kalivas PW (1991) Sensitization to psychostimulants and stress after injection of pertussis toxin into the AlO dopamine region. J Pharmacol Exp Ther 259:916-924.
58. Stine SM, Krystal JH, Kosten TR and Charney DS (1995) Mazindol treatment for cocaine dependence. Drug Alcohol Depend 39:245-252.
59. Tella SR, Ladenheim B, Andrews AM, Goldberg SR and Cadet JL (1996) Differential reinforcing effects of cocaine and GBR 12909: Biochemical evidence for divergent neuroadaptive changes in the mesolimbic dopaminergic system. J Neurosci 16: 7416-7427.
60. van der Zee P and Hespe W (1978) A comparison of the inhibitory effects of aromatic substituted benzhydryl ethers on the uptake of catecholamines and serotonin into synaptosomal preparations of the rat brain. Neuropharmacology 17:483-490.
61. van der Zee P, Koger HS, Gootjes J and Hespe W (1980) Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur J Med Chem 15:363-370.
62. Vaugeois JM, Bonnet JJ, Duterte-Boucher D and Costentin J (1993) In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur J Pharmacol 230:195-201.
63. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Galley SJ, Pappas N, Hitzemann R and Shea CE (1997) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature (London) 386:827-830.
64. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Ding YS, Logan J, Dewey SL, Hitzemann R and Lieberman J (1996) Relationship between psychostimulant-induced "high" and dopamine transporter occupancy. Proc Natl Acad Sci USA 93:10385-10392.
65. Wilson MC and Schuster CR (1975) Interactions between atropine, chlorpromazine, and cocaine on food-reinforced behavior. Pharmacol Biochem Behav 3:363-675.
66. Wise RA (1984) Neural mechanisms of the reinforcing action of cocaine. NIDA Research Monograph 50:15-433.
67. Witkin JM (1994) Pharmacotherapy of cocaine abuse: Preclinical development. Neurosci Biobehav Rev 18:121-142.
68. Woolverton WL and Johnson KM (1992) Neurobiology of cocaine abuse. Trends Pharmacol Set 13:193-200.
69. Zolman JF (1993) Biostatistics: Experimental Design and Statistical Inference, Oxford University Press, New York.